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Abstract: Since their introduction in 1959, development of hormonal contraceptives has been 
ongoing, with the ultimate aim of creating not only an effective and safe contraceptive method, 
but also a drug able to meet the need for treatment of other conditions, such as acne, seborrhea, 
and hirsutism, with few or no side effects. With this objective, a new progestin, chlormadinone 
acetate (CMA), has been developed as a derivative of progesterone for  contraception. This 
new molecule has been introduced in combination with ethinylestradiol (EE) 30 µg as a safe 
 contraceptive with antiandrogenic properties. Many clinical studies have investigated this new 
oral combination and found it to be safe, with a Pearl Index similar to that of other combined 
hormonal contraceptives. CMA, because of its antiandrogenic properties, has been also con-
sidered effective for resolution of acne, seborrhea, and hirsutism. The data show it to be a 
safe molecule in terms of glucose and lipid metabolism. No major weight changes have been 
linked with its use, and it seems to be the only progestin able to reduce fat mass during use. 
The CMA-EE combination is well tolerated and acceptable to women. Adverse events related 
to its use are similar to those reported with other third-generation  contraceptives. We can 
conclude that CMA-EE is an effective, safe, and well tolerated  antiandrogenic hormonal 
contraceptive.
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Introduction
The use of combined oral contraceptive pills has steadily increased since their 
introduction in 1960. Currently over 80 million women worldwide rely on hormonal 
contraception, expecting it to provide optimal contraceptive efficacy with a reliable 
tolerability profile, and additional benefits for well being. After the first oral 
contraceptive products became available to the general population, concern about 
adverse reactions led to a modification in their composition, ie, a lower estrogen dose 
and the introduction of new progestogens. Chlormadinone acetate (CMA), a synthetic 
progestogen, in combination with ethinylestradiol (EE), was approved in Germany in 
1998 as a combined hormonal oral contraceptive.
CMA is a derivative of 17-alfa-hydroxyprogesterone. In in vitro studies, CMA 
showed a high affinity for progesterone receptors, about one-third higher than for 
progesterone itself.1 CMA , like the other antiandrogenic progestogens, shows no 
affinity for estrogen receptors in vitro, suggesting an absence of estrogenic effects at 
clinically relevant doses.2 The progestogenic activity of CMA produces a negative 
feedback on gonadotropin secretion, leading to inhibition of ovulation and reduced 
androgen biosynthesis.3 CMA also has antiandrogenic properties, mainly exerted 
Open Access Journal of Contraception 2010:1submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
94
Ferrari et al
by blockade of androgen receptors in target organs, but 
also by reduction of activity in sebaceous glands and hair 
follicles by 5-alpha reductase, the enzyme responsible for 
converting testosterone to the more potent androgen, 5-alpha 
dihydrotestosterone.4 Furthermore, CMA does not compete 
with androgens for sex hormone-binding globulin and, 
by suppressing gonadotropin secretion, it reduces ovarian 
androgen production. CMA has negligible or no systemic 
glucocorticoid, mineralocorticoid, or antimineralocorticoid 
effects at clinically relevant doses.5
Pharmacokinetics
After oral administration, CMA is almost completely 
absorbed at peak plasma concentration in 1–4 hours, and 
its bioavailability is almost 100%. During multiple dose 
administration, CMA exhibits linear time-dependent 
pharmacokinetics, with little accumulation in plasma. 
Multiple dose administration has little impact on peak plasma 
concentrations, although the terminal elimination half-life 
is increased compared with single-dose administration. 
Nevertheless, steady-state plasma concentrations are 
achieved within 8–15 days. CMA is over 96% bound to 
plasma albumin.6 Antiandrogenic progestogens have no 
affinity for sex hormone-binding globulin, and therefore 
they do not displace androgens from their carrier proteins.7 
Importantly, CMA does not antagonize the EE-induced 
increase in sex hormone-binding globulin production.8 
CMA is highly lipophilic, so is taken up by body fat and 
is also stored in some reproductive tissues, such as the 
myometrium, cervix, and fallopian tubes.9 Storage in body 
fat slows elimination, but clinically relevant accumulation 
of CMA (which may be manifested by delayed withdrawal 
bleeding) is only apparent in some women taking high doses 
($10 mg/day) to treat androgen-related conditions.7
CMA undergoes extensive hepatic metabolism before 
excretion in the urine and feces. The main metabolites of 
CMA in human plasma are its 2α-, 3α-, and 3β-hydroxy 
derivatives, although a wide variety of other reduced, 
hydroxylated, and deacetylated metabolites are also formed.7 
There is some controversy over the activity of the 3α- and 
3β-hydroxy metabolites. Animal studies have indicated 
them to be antiandrogenic, while others suggest that this 
activity might result from back-transformation into CMA 
because an intact 3-keto group appears to be essential for 
androgen receptor binding. Other CMA metabolites are 
inactive.10 Because of its extensive distribution in fat, CMA 
is excreted slowly, with terminal elimination half-life values 
of around 25 hours after a single dose and 36–39 hours after 
multiple doses. CMA is excreted approximately equally in 
the urine and feces (45% and 42%, respectively).11
Efficacy
Contraceptive efficacy
On the basis of many dedicated studies, the  combination of 
CMA-EE can be described as an effective oral contraceptive. 
A Phase II, single-center, open, uncontrolled trial was 
performed to evaluate the efficacy of CMA-EE in the 
prevention of pregnancy. The main outcome measure was 
inhibition of ovarian activity, assessed by frequent ultrasound 
monitoring of the presence, size, and persistence of follicle-like 
structures.  Secondary parameters included cervical reaction 
score (ie, probability of fertilization), endometrial thickness 
(probability of implantation), and serum levels of the sex 
hormones estradiol, progesterone, luteinizing hormone, and 
follicle-stimulating hormone. Thirty-three subjects were eli-
gible for the trial and were included in the efficacy assessment 
(per protocol analysis). All subjects  ovulated during the 
pretreatment cycle, but none ovulated during the three medi-
cation cycles. Follicular growth was profoundly suppressed 
during the medication phase, with residual ovarian activity 
occurring in only 12/83 (14.5%) treatment cycles. The cervi-
cal reaction score was negative during each medication cycle, 
and endometrial thickness was suppressed on each medication 
day, with median values of 4.0–6.0 mm.12
An open, uncontrolled Phase III study evaluated the CMA-
EE combination in terms of efficacy. A total of 1655 women, 
who were patients of 75 office-based gynecologists in 
Germany, participated in the study and were treated with 
CMA-EE for #24 cycles, ie, a total of 22,337 cycles. Twelve 
pregnancies occurred during the study. The actual Pearl Index 
was 0.645 (95% confidence interval [CI]: 0.359–1.092); in 
seven of these pregnancies, conception occurred because 
of intake errors, concomitant administration of antibiotics, 
diarrhea, or vomiting. Thus, the theoretic Pearl Index in this 
study was 0.269 (95% CI: 0.109–0.600). The cumulative 
12-cycle pregnancy rate was 0.00232 (95% CI: 0.0–0.0049) 
considering only the pregnancies contributing to the theo-
retic Pearl index, and 0.00525 (95% CI: 0.00135–0.00914) 
considering all pregnancies. After 24 cycles, the cumulative 
pregnancy rate was 0.0046 (95% CI: 0.00047–0.00873) and 
0.01385 (95% CI: 0.0038–0.0239), respectively.13
Another open, multicenter, observational clinical evalua-
tion was conducted, also in Germany, in which 2620 patients 
from 435 gynecologic practices were treated for ,12 months. 
The analysis thus encompassed 29,262 cycles of exposure. 
Ten women became pregnant during the 12-month observa-
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tion period. Thus, the unadjusted Pearl Index was calculated 
to be 0.4 (95% CI: 0.2–0.8). However, intake errors were 
considered to be responsible for 90% of the undesired preg-
nancies, which included at least 8/9 patients who forgot to 
take the pill on several occasions. After review, in only one 
case was a method failure stated as possible, resulting in an 
adjusted Pearl Index of 0.04 (95% CI: 0.002–0.2).14
Another trial involved 3772 women aged $25 years 
who used contraception for six cycles with a conventional 
or extended cycle regimen. The total number of observed 
cycles was 21,642.25 for both the conventional cycle regimen 
(20,707 cycles) and extended cycle regimen (363 extended 
cycles, ie, 935.25 cycle equivalents at 28 days), with an obser-
vation period of 1665 women-years (based on 13 cycles/cycle 
equivalents of 28 days). The conventional cycle regimen for 
CMA-EE (21-day pill intake [one blister strip pack] followed 
by a seven-day, pill-free interval) was used by 3578 (94.9%) 
women, with only a minority of women (n = 194, 5.14%) using 
an extended cycle regimen with a consecutive pill intake of two 
to six (most often three) blister strip packs of CMA-EE (n = 116, 
59.79%) followed by a seven-day, pill-free interval.
A total of 3276 (86.85%) women reported regular intake 
of CMA-EE, whereas the remainder missed at least one 
(n = 369) or more (n = 127) tablets per cycle/blister strip 
pack. Despite these irregularities, no pregnancy occurred 
during CMA-EE treatment. This resulted in a Pearl Index of 
0 (95% CI: 0.00–0.22).15
The efficacy of CMA-EE (2 mg and 20 µg, respec-
tively) was also confirmed during the extended regi-
men. Six pregnancies occurred during 21,495 evaluable 
cycles, resulting in an overall Pearl Index of 0.36 (95% 
CI: 0.13–0.79). This corresponds to an overall Pearl Index 
for the first year of use in women aged 18–40 years (17,031 
cycles in 1653 subjects) and in women aged up to 35 
years (15,668 cycles in 1524 subjects) of 0.31 and 0.33, 
respectively.
The cumulative one-year pregnancy rate for the overall 
Pearl Index was 0.31% (95% CI: 0%–0.61%), corresponding 
to more than 99% contraceptive protection over one year. In 
five of six pregnancies, conception occurred at time points 
for which the efficacy of CMA-EE (2 mg and 0.02 mg, 
respectively) was reduced due to vomiting, diarrhea, and 
intake errors. Only one pregnancy was attributable to method 
failure.16
Acne
Acne is a common skin disorder characterized by overpro-
duction of sebum leading to noninflammatory (comedones) 
and inflammatory (papules, pustules, nodulocystic lesion) 
skin conditions. Most women with acne suffer from a 
 hypersensitivity of the sebaceous glands to androgen, but 
frequently an excess of androgen can be observed. The use 
of an oral contraceptive with antiandrogenic properties has 
proven to be a useful approach towards this problem. A study 
developed by Worret et al17 compared the effects of two 
low-dose estrogen-progestogen combinations, ie, CMA-EE 
and EE in combination with levonorgestrel (LNG-EE), in 
199 women with mild to moderate papulopustular acne. The 
primary endpoint was achieved if the number of  papules/
pustules per half of the face present on admission had 
decreased by at least 50% in medication cycle 12. In total, 
for papulopustular facial acne, 59.4% patients on CMA-EE 
and 45.9% patients on LNG-EE were responders according 
to the definition of the primary endpoint; this superiority 
was statistically significant. Similar trends could be detected 
for comedonal facial acne by cycle 12. With CMA-EE, an 
improvement of 88.9% was seen compared with 77.3% in the 
LNG-EE group. The improvement rates for papulopustular 
or comedonal acne were 95.6% and 91.9%, respectively, on 
CMA-EE compared with 81.1% and 73.1% on LNG-EE. 
Papulopustular acne, as well as comedonal acne of the back, 
improved in almost 100% patients on CMA-EE (97.7% and 
97.3%, respectively) and in a smaller number of patients on 
LNG-EE (87.9% and 76.9%, respectively).
Another double-blind, randomized (2:1), placebo-
 controlled, parallel, multinational Phase III trial was 
 conducted to evaluate acne resolution on CMA-EE.18 This 
trial showed clearly that CMA-EE was superior to placebo 
in the treatment of moderate acne, irrespective of the kind of 
lesion or the body area under investigation. The trial included 
387 subjects from 28 European centers. Ten subjects did not 
take any study medication and were therefore excluded from 
evaluation. Therefore, the analysis included 251 subjects ran-
domized to receive CMA-EE and 126 to placebo. The primary 
endpoint of the study was  reduction of moderate papulopustu-
lar facial acne. The rate of response was significantly higher 
in the CMA-EE group, ie, 64.1% (161/251) compared with 
43.7% (55/126) for placebo (P = 0.0001). A similar trend in 
favor of CMA-EE was observed for moderate comedonal 
facial acne. During treatment, a continuous reduction in come-
dones occurred in both groups, but a pronounced effect was 
observed in women on CMA-EE. By medication cycle 6, the 
median relative decrease in comedones of the face was 54.8% 
in the CMA-EE group but only 32.4% in the placebo group 
(between-group difference P = 0.0006). In cycles 3 and 6, 
the P value for the between-group difference in relation to 
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the relative change from baseline in comedone number was 
P , 0.05. On admission, 64.9% (163/251) of subjects in the 
CMA-EE group and 74.6% (94/126) in the placebo group 
had moderate acne. In this subgroup analysis, the number 
who experienced complete resolution of moderate acne on 
the décolleté increased continuously over the six cycles, with 
48.5% (79/163) of CMA-EE subjects and 29.8% (28/94) 
placebo subjects, having no moderate acne in this area at all by 
the end of the trial. The median relative decrease from baseline 
in papules and/or pustules over six cycles was 92.9% in the 
CMA-EE group compared with only 50.0% in the placebo 
group (P , 0.05 at cycle 3 and cycle 6). Prevalence of mod-
erate acne on the back was high, ie, 80.1% (201/251) in the 
CMA-EE group and 86.5% (109/126) in the placebo group at 
baseline. There was a continuous reduction in papulopustular 
lesions on the back over six cycles in the CMA-EE group, 
resulting in a median relative decrease of 86.0% compared 
with 58.3% in the placebo group. The P value for the relative 
difference between groups versus baseline was P , 0.05 for 
cycles 3 and 6. Complete resolution of moderate acne lesions 
on the back was found in 41.8% of the CMA-EE group and 
24.8% of the placebo group.
An open-label, prospective, single-center Phase IV study 
investigated the effects of CMA-EE on the physiology of 
acne-prone facial skin in healthy women aged 18–37 years.19 
The condition of facial skin, as quantified by a clinical 
summation score, improved significantly after three and 
six treatment cycles, with reduced numbers of acne lesions 
(comedones and papules/papulopustules) and a reduction in 
degree of seborrhea. Skin surface pH remained within the 
normal physiologic range, and there was an improvement 
in epidermal barrier function (as manifested by decreased 
transepidermal water loss from the skin of the forehead). 
Stratum corneum hydration increased, and the lipid content 
of the skin surface on the forehead decreased.
The superiority of CMA-EE for acne improvement in 
comparison with other contraceptive methods has also been 
demonstrated in another study20 which observed users of 
oral contraceptives, intrauterine devices, and intrauterine 
systems, who switched voluntarily to CMA-EE treatment 
because of dissatisfaction with their earlier contraceptive 
regimen. The majority of study participants (12,088, 72.0%) 
complained about seborrhea and/or acne while on their 
previous hormonal contraceptive regimen. Before and after 
four cycles of CMA-EE, data for this complaint were avail-
able for 11,638 women. In almost half of them (45.9%), 
seborrheic symptoms disappeared completely after switching 
to CMA-EE during a four-cycle treatment. Acne/seborrhea 
improved in another 36.5% (n = 4248). Acne can have a 
profound negative impact on well-being, particularly during 
adolescence. A study in this population found CMA-EE to be 
a good contraceptive compared with drospirenone (DRSP). 
Prior to the study, 90 adolescents (55.5%) complained of 
acne, and 84 (52.4%) complained of skin disorders with a 
predominance of greasy skin. Objective amelioration of skin 
and hair features was found in both groups, but there was 
a significantly greater benefit in CMA users compared with 
DRSP users at the end of the study (P , 0.01).21
Seborrhea and hirsutism
The studies that investigated acne in women taking CMA-
EE also investigated seborrhea and hirsutism. In comparison 
with placebo, total resolution of seborrheic symptoms was 
observed in 41.5% of subjects taking CMA-EE and in 23.9% 
taking placebo (95% CI: 51.1–65.6 and 65.9–84.6, respec-
tively).18 Seventeen percent of subjects experienced total 
resolution of hirsutism in the CMA-EE group versus 8.8% 
in the placebo group (95% CI: 70.6–91.4 and 76.3–98.1, 
respectively). In comparison with LNG-EE,17 an improvement 
in seborrhea and hirsutism was confirmed. At baseline, 31.7% 
of women on CMA-EE and 30.6% on LNG-EE suffered from 
seborrhea. In both treatment groups, there was a decrease 
in the number of women with seborrhea after 12 treatment 
cycles; 80.0% in the CMA-EE group showed total resolution 
versus 76.2% in the LNG-EE group. Hirsutism, irrespective of 
body localization, was present in 13.9% of patients allocated 
to CMA-EE and in 20.4% on LNG-EE at baseline. Hirsutism 
disappeared completely in about one-third of women in each 
treatment group after 12 cycles of treatment. Even if these 
data can be considered only a trend because of the small 
patient population, it is possible to consider CMA to have a 
good profile also in hirsutism.17
Safety
Over the years many studies have investigated the safety 
profile of hormonal contraception. The attention of clinicians 
was mainly focused on the most important risk factors for 
thrombosis and cardiovascular diseases (hemostatic param-
eters, blood pressure, lipids, and glucose metabolism).
An increased risk of thromboembolic events with oral 
contraceptives has been recognized since 1970. In par-
ticular, this risk was attributed to the estrogen dose, and 
later to the type of progestin in the combination. The effect 
of CMA-EE on hemostatic parameters was evaluated in 
45 volunteers  randomly assigned to six months of treatment 
with CMA-EE or a combination desogestrel (DSG)-EE oral 
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contraceptive pill. This study demonstrated that both oral 
contraceptive combinations had comparable effects on the 
hemostatic system. There was a shift towards a new equilib-
rium of hemostatic activity, both coagulatory and fibrinolytic, 
with a higher turnover rate. The changes did not exceed 
the normal range and were comparable with the published 
effects of other low-dose hormonal contraceptives. In par-
ticular, increased plasma levels of fibrinogen, Factor VII, 
VIII, and XIII activity, and prothrombin fragments 1 and 2 
were documented for CMA-EE. Plasma levels of thrombin-
antithrombin complexes showed no alteration. A decrease in 
antithrombin III and protein S activity was found, as well as a 
decrease in activated protein C sensitivity and an increase in 
protein C activity. The use of CMA-EE was associated with 
an increase in plasmin-antiplasmin complexes, D-dimer, and 
total fibrin degradation products. Both tissue plasminogen 
activator and its inhibitors decreased considerably, but the 
decrease in plasminogen activator inhibitor-1 exceeded the 
decrease in tissue plasminogen activator, suggesting the sur-
plus activity of the fibrinolytic system was associated with a 
reduced threshold of fibrinolytic inhibition.22
A second study was conducted using CMA in combina-
tion with a lower EE dose of 20 µg. Thrombin/fibrin turnover 
was assessed by analysis of D-dimer concentrations and 
prothrombin fragment 1 and 2 concentrations. The median 
D-dimer values (fibrin turnover) did not change between 
baseline and CMA-EE cycle 6. Median prothrombin frag-
ment 1 and 2 values (thrombin turnover) increased by 
33.3% between baseline and medication cycle 6 (P , 0.05 
compared with baseline) during treatment with CMA-EE. 
The majority of changes in prothrombin fragment 1 and 2 
and D-dimer remained within the reference range. Median 
values for all procoagulatory parameters (fibrinogen, and 
Factor II, VII, and VIII activity) increased between baseline 
and medication cycle 6. During the postmedication cycle, 
these changes returned towards baseline values. Between 
80%–95% of all fibrinogen and Factor VIII activity values 
remained within the reference range throughout the trial. 
Factor II and VII activity changed from normal at baseline 
to above the upper limit of normal at medication cycle 6. 
The median values for the anticoagulatory parameters, 
activated partial thromboplastin time, activated protein C 
sensitivity ratio, antithrombin III activity, and free protein 
S decreased to a small extent (,15% change from baseline), 
or remained unchanged between baseline and medication 
cycle 6. In contrast, protein C activity and endogenous throm-
bin potential-based activated protein C resistance increased 
between baseline and medication cycle 6 (P , 0.05). Most 
changes returned towards baseline during the postmedication 
cycle.  Plasminogen, a profibrinolytic parameter, increased 
(P , 0.05) and tissue plasminogen  activator decreased 
(P , 0.05) between  baseline and medication cycle 6. Plas-
minogen activator inhibitor Type 1 antigen (an antifibrin-
olytic parameter), decreased by 4%–69%. The majority of 
the changes during medication cycle 6 remained within the 
reference range, and most changes returned towards baseline 
during the postmedication cycle.23 CMA-EE was associated 
with a lower risk of deep vein thrombosis than other third-
generation hormonal contraceptives.13,14,22
CMA-EE has a neutral effect on blood pressure. Systolic/
diastolic blood pressure and heart rate remained unchanged 
in 1600 women during administration of CMA-EE.13 Blood 
pressure was unchanged also during longer treatment or 
during an extended regimen.14–16 Many studies have dem-
onstrated that lower-dose oral contraceptives have no clini-
cally relevant influence on glucose metabolism, including 
development of diabetes mellitus. Glucose intolerance and 
insulin resistance are associated with an increased risk of 
atherosclerosis and cardiovascular disease. A trial evaluating 
metabolic changes during use of CMA investigated changes 
in blood glucose and insulin levels with the oral glucose 
tolerance test. Treatment with CMA-EE (2 mg and 30 µg, 
respectively) increased blood glucose levels compared with 
baseline during the oral glucose tolerance test, although the 
values were still within the reference range. Insulin plasma 
levels were also slightly increased in parallel with the raised 
glucose levels. None of the subjects in the treatment group 
had an abnormal oral glucose tolerance test suggestive of 
impaired glucose tolerance or diabetes mellitus.24
The oral glucose tolerance test is not appropriate for eval-
uation of insulin sensitivity, reduction of which represents 
the first step in deterioration of glucose metabolism. Insulin 
sensitivity was investigated with a frequently sampled intra-
venous glucose tolerance test and the minimal model method 
in 39 women on an oral contraceptive containing DSG versus 
an oral contraceptive containing CMA.25 The results showed 
that the two contraceptive agents act differently. DSG-EE 
significantly decreases insulin sensitivity, while CMA-EE 
does not (Figure 1). This difference is probably related to 
the androgenic properties of DSG.25 Neutrality of CMA-EE 
on insulin sensitivity is important because it indicates that 
the compound does not favor development of the metabolic 
syndrome, of which insulin resistance and glucose metabo-
lism alteration are the key determinants.
Data on lipids and lipoproteins are reassuring. A safety 
study was done in 1998 on 1655 women for a total of 
Open Access Journal of Contraception 2010:1submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
98
Ferrari et al
22,337 cycles. In this study, it was reported that total triglyc-
erides and very low-density lipoproteins (VLDL) increased 
during CMA-EE treatment, but on the other hand, the increase 
in median high-density lipoprotein (HDL) levels and a corre-
sponding marked decrease in median low-density lipoprotein 
(LDL) values led to a decreased LDL:HDL ratio.13 A Phase 
III study performed in Germany claimed, without reporting 
data, an increase in total cholesterol and LDL levels, with a 
slight increase in mean HDL, and a slight increase in median 
VLDL, with no overall change in the LDL:HDL ratios.26 
These data were recently confirmed and published for a small 
number of subjects, in whom CMA-EE was associated with 
elevated HDL and triglycerides, and these effects were strong 
enough to increase the HDL:LDL and Apo A1:Apo B ratios 
significantly (Figure 2).25 The relative risk of developing 
cardiovascular disease is inversely related to plasma HDL 
and Apo A1 concentrations and the LDL:HDL ratio, so all 
these findings show no evidence that CMA-EE increases the 
risk of atherogenic disease during long-term use.
Lipid metabolism has also been investigated during 
an extended regimen of CMA-EE. Although mean total 
cholesterol and LDL levels increased slightly during the 
study, there was also a slight increase in mean HDL. Con-
sequently, there was no overall change in the LDL:HDL 
or total cholesterol:HDL ratios. Therefore, consistent with 
experience from use of other low-dose oral contraceptives, 
there is no evidence that CMA-EE (2 mg and 0.03 mg, 
respectively) increases the risk of developing atherosclerosis 
during long-term use.16
Tolerability
Cycle control
A postmarketing surveillance study of CMA-EE shows it 
to be a well tolerated oral contraceptive. A “very good” or 
“good” tolerability was reported by 8.5% of women.27 During 
treatment, 69.6% of women did not experience any  bleeding 
disorder. Withdrawal bleeding was assessed to be mild in 
6977 (32.0 versus 21.9% at baseline), normal in 13,457 
(61.7 versus 62.6% at baseline), and severe in 267 women 
(1.2 versus 14% at baseline). Both severe withdrawal bleed-
ing and dysmenorrhea decreased markedly on CMA-EE. 
Almost two-thirds of women who previously experienced 
intracyclic bleeding reported that these symptoms had disap-
peared on CMA-EE. This was also the case for more than 
90% of women with previous amenorrhea. About one-third 
of all patients did not experience any intermenstrual bleeding 
(spotting) or breakthrough bleeding, and the rates of cycles 
without intracyclic bleeding increased with the duration of 
study treatment. Amenorrhea was limited to a very low rate 
of only 1.0% for all cycles.27
Good cycle control with CMA-EE was also reported in a 
larger study conducted in 2620 women. While on CMA-EE, 
67.3% of these women did not experience any bleeding 
 problems. Slight spotting, breakthrough bleeding, and amen-
Insulin sensitivity
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Figure 1 Mean (±Se) peripheral insulin sensitivity (units ± 10−4 min−1 µ/mL) observed in healthy young women before and after six months of treatment with DSG-ee (n = 12) 
or CMA-ee (n = 12); *P = 0.04 versus corresponding baseline values.25 
Abbreviations: CMA-ee, chlormadinone acetate-ethinylestradiol; DSG-ee, desogestrel-ethinylestradiol; Se.
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orrhea were documented in 26.6%, 7.1%, and 6.4% of the 
total study population, respectively. In women with a history 
of regular cycles, the rates of menstrual bleeding problems 
were always below the average for all patients (spotting 21%, 
breakthrough bleeding 5.7%, and amenorrhea 5.4%). In 81.4% 
of women with no withdrawal bleeding, it was reported that 
amenorrhea occurred only in one cycle. Intermenstrual bleed-
ing was most common during the first treatment cycle, and 
thereafter its incidence decreased. In 61.7% of women who 
suffered from intermenstrual bleeding in the last two cycles 
before the start of the study, the symptoms were no longer 
present when on CMA-EE. Amenorrhea disappeared in 89.3% 
of these women.14
In comparison with DRSP, women using CMA had a 
significantly greater improvement of irregular bleeding after 
three cycles of therapy, which was progressive until the end 
of the observation period (CMA versus DRSP, P , 0.001). 
The same trend was found for mild and moderate dysmenor-
rhea (CMA versus DRSP P , 0.01).21
Menstrual cycle irregularities are common in women when 
switching their method of contraception. The results of a pro-
spective observational study in 20,897 women revealed that 
87.0% (n = 2731) of participants who described their previ-
ous cycles as irregular reported regular cycling on CMA-EE. 
Irregular cycling was documented in only 6.9% (n = 217) of 
women during the observation period. In total, 6073 women 
(36.2%) complained of spotting and  breakthrough bleeding on 
their previous contraceptive regimen, but only 2391 women 
(14.2%) has this complaint on CMA-EE. The number of 
women suffering from these symptoms decreased substan-
tially to 3723 (22.2%) and 692 (4.1%), respectively, after 
four cycles of CMA-EE. The incidence of severe withdrawal 
bleeding dropped from 7.5% at baseline to 0.9% at the end 
of the evaluation period. A total of 2490 (100%) women 
switched to the CMA-containing contraceptive because of 
secondary amenorrhea. On CMA-EE, bleeding occurred 
regularly in 87.6% (n = 2180) of these women. If bleeding 
disorders were newly diagnosed during CMA-EE treatment, 
these difficulties mostly occurred in the first two cycles and 
became less frequent during further treatment.20
Body weight
CMA-EE is not linked with weight gain for the majority of 
women. In a study of long-term use, mean weight change 
was 0.8% in cycle 2, 0.75% in cycle 4, 1.0% in cycle 10, 
and 0.22% in cycle 22.13 This good profile was confirmed 
by another study in 2620 women over 12 cycles, in which 
78.8% of 2620 women did not experience major weight 
changes (loss or increase .2 kg) during CMA-EE, 24.5% 
of women did not report any weight change, and 36.5% 
did experience a weight gain of 1–2 kg.14 These findings 
were confirmed by a study in which body composition was 
Lipid metabolism
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Figure 2 Mean (+Se) ApoA1/APo B observed in healthy young women before and after six months of treatment with DSG-ee (n = 12) or CMA-ee (n = 12); *P = 0.048 
versus corresponding baseline values.25 
Abbreviations: CMA-ee, chlormadinone acetate-ethinylestradiol; DSG-ee, desogestrel-ethinylestradiol; Se.
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 evaluated using multifrequency bioelectrical impedance 
analysis in 24 women during the follicular phase before 
and after three and six cycles of CMA-EE. Mean values 
for body weight, body mass index, and waist-to-hip ratio 
did not vary during the study. Total body water, extracel-
lular water, intracellular water, and fat free mass remained 
unchanged on CMA-EE. During treatment, mean fat mass 
was 13.5 ± 1.0 kg after three months and 12.7 ± 1.0 kg 
after six months. These values were significantly lower 
than the baseline values (14.2 ± 1.0 kg). The results of 
this study seem to show that a six-cycle treatment with 
an oral contraceptive containing CMA-EE is associated 
with a decrease in fat mass.28 This is unexpected in light of 
previous studies of other contraceptives containing differ-
ent progestin compounds, such as LNG and DRSP, which 
did not show similar effects on fat mass.20,30 The effect of 
CMA-EE in reducing fat mass is important in preventing 
cardiovascular disease, diabetes, and breast cancer, and is 
also important for women afraid of gaining weight during 
hormonal contraception.29
The reported adverse events with CMA-EE reflect the 
spectrum of complaints usually observed during use of 
oral contraceptives. The most frequently reported adverse 
events observed for the first time by participants in CMA-EE 
studies were headache (37.4%), nausea (23.1%), breast 
tenderness (21.7%), and vaginal discharge (19.4%). The 
description of symptoms showed maximum occurrence at 
the start of use, with a decrease in all symptoms in the fol-
lowing cycles. Some serious adverse events also occurred. 
Accidents and musculoskeletal injuries occurred in 0.66% 
of women, along with ovarian cyst surgery (0.42%), hear-
ing impairment (0.18%), and goiter (0.18%). Two proven 
cases of deep venous thrombosis and one case of pulmonary 
embolism occurred during the study.13 Similar findings 
have been reported in a postmarketing surveillance study in 
2620 women. Only one adverse event was found in 85.4% 
in women, whereas 13.0% and 1.7%, respectively, recorded 
two or three adverse events. The most frequently reported 
adverse events, observed by women for the first time whilst 
on the study medication or which intensified during the 
observation period, were breast pain in 4.6%, migraine/
headache in 2.7%, gastrointestinal disorders and weight gain 
in 0.9%, and a depressive state in 0.8%. With longer dura-
tion of CMA-EE intake, the occurrence of adverse events 
became less frequent. It was also reported that 32.3% of 
adverse events were evaluated as mild, 34.6% as moderate, 
and 23.4% as severe. One case of deep venous thrombosis 
was identified.14
During an extended regimen of CMA-EE (2 mg and 
20 µg, respectively) in 147 women over 424 months of obser-
vation, no unexpected (including serious) adverse events were 
observed. The most frequent adverse events, ie, headache, 
breast pain, nausea, and tiredness are known to be associ-
ated with oral contraceptive use. There was only one throm-
boembolic event that occurred in a woman aged .30 years 
who smoked and had also experienced a recent period of 
immobility as a result of a twisted ankle.16
Acceptability
The CMA-EE combination is well tolerated from the per-
spective of both women and clinicians. In one study, after 
12 cycles of treatment, almost 85% of women and more 
than 90% of clinicians have reported tolerability to be “very 
good” or “good”.14 Only a minority of women (4.4%) and 
clinicians (1.4%) assessed tolerability to be “moderate” or 
“poor”, and 76.4% of women expressed a wish to continue 
with CMA-EE after the end of the study.
Similar data were found for women who decided to 
switch to CMA-EE from other contraceptive. Well-being 
was reported by 85.9% of women as “very good” or “good”, 
while 61% rated it as moderate, and only 1.6% described 
poor well-being. Compared with their previous contraceptive 
regimen, 80.5% of women reported being more satisfied or 
much more satisfied with CMA-EE.21
CMA-EE was also assessed as “very good” in terms of 
both physical and emotional symptoms by more than 90% 
of women using this contraceptive. General well-being was 
reported by 93% of women.15
Disclosure
The authors report no conflicts of interest in this work.
References
1. Handy RW, Palmer KH, Wall ME, Piantadosi C. The metabolism of 
antifertility steroids: The in vitro metabolism of chlormadinone acetate. 
Drug Metab Dispos. 1974;2(3):214–220.
2. Kuhl H. Pharmacokinetics of oestrogens and progestogens. Maturitas. 
1990;12(3):171–197.
3. Neumann F. The antiandrogen cyproterone acetate: Discovery, chemistry, 
basic pharmacology, clinical use and tool in basic research. Exp Clin 
Endocrinol. 1994;102(1):1–32.
4. Rabe T, Kowald A, Ortmann J, Rehberger-Schneider S. Inhibition of 
skin 5 alpha-reductase by oral contraceptive progestins in vitro. Gynecol 
Endocrinol. 2000;14(1):223–230.
5. Neumann F. The physiological action of progesterone and the phar-
macological effects of progestogens: A short review. Postgrad Med J. 
1978;54 Suppl 2:S11–S24.
6. Belara® product monograph. 1st ed. Grünenthal, GmbH, Germany.
7. Kuhl H. Chemie und pharmakologie von chlormadinonacetat. In: Loch 
EG, Schramm G, editors. Chlormadinonacetat bei Androgenisierung-
serscheinungen. Stuttgart: Schattauer; 1995.
Open Access Journal of Contraception
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/open-access-journal-of-contraception-journal
Open Access Journal of Contraception is an international, peer-
reviewed, open access, online journal, publishing original research, 
reports, reviews and commentaries on all areas of contraception. In 
addition to clinical research, demographics and health-related aspects, 
the journal welcomes new findings in animal and preclinical studies 
relating to understanding the biological mechanisms and practical 
development of new contraceptive agents. The manuscript manage-
ment system is completely online and includes a very quick and fair 
peer-review system. Visit http://www.dovepress.com/testimonials.php 
to read real quotes from published authors.
Open Access Journal of Contraception 2010:1 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
101
Chlormadinone acetate-ethinylestradiol OCP
 8. van der Vange N, Blankenstein MA, Kloosterboer HJ, Hasples AA, 
Thijssen JH. Effects of seven low-dose combined oral contraceptives 
on sex hormone binding globulin, corticosteroid binding globulin, total 
and free testosterone. Contraception. 1990;41(4):345–352.
 9. Gallegos AJ, Gonzales-Diddi M, Merino M, et al. Tissue localisation 
of radioactive chlormadinone acetate and progesterone in the human. 
Contraception. 1970;1:151–161.
 10. Handy RW, Hess TR, Wall ME. Comparative metabolism of chlorma-
dinone acetate. [Abstract]. The Pharmacologist. 1973;15:228–233.
 11. Terlinden R, Uragg H, Gohler K, Kneip C. Pharmacokinetics of chlo-
rmadinone acetate following single and multiple oral dosing of chlorma-
dinone acetate (2 mg) and ethinylestradiol (0.03 mg) and elimination 
and clearance of a single dose of radiolabeled chlormadinone acetate. 
Contraception. 2006;74(3):239–244.
 12. Spona J, Binder N, Höschen K, Feichtinger N. Contraceptive efficacy 
and safety of a low-dose oral contraceptive, (0.03 mg ethinyl oestradiol 
and 2 mg chlormadinone acetate) Belara®, over three medication cycle. 
Eur J Contracept Reprod Health Care. 2008;13(1):39–48.
 13. Zahrandnik HP, Goldberg J, Andreas JO. Efficacy and safety of the 
new antiandrogenic oral contraceptive Belara. Contraception. 1998; 
57(2):103–109.
 14. Schramm G, Steffens D. A 12-months evaluation of the CMA- 
 containing oral contraceptive Belara: Efficacy, tolerability and anti-
androgenic properties. Contraception. 2003;67(4):305–312.
 15. Heskamp ML, Schramm GA. Efficacy of the low-dose combined oral 
contraceptive chlormadinone acetate/ethinylestradiol: Physical and 
emotional benefits. Contraception. 2010;81(1):49–56.
 16. Brucker C, Hedon B, The HS, Höschen K, Binder N, Christoph A. 
Long-term efficacy and safety of a monophasic combined oral contra-
ceptive containing 0.02 mg ethinylestradiol and 2 mg chlormadinone 
acetate administered in a 24/4-day regimen. Contraception. 2010; 
81(6):501–509.
 17. Worret I, Arp W, Zahradnik HP, Andreas JO, Binder N. Acne resolution 
rates: Results of a single-blind randomized controlled parallel phase III 
trial with EE/CMA (Belara) and EE/LNG (Microgynon). Dermatology. 
2001;203(1):38–44.
 18. Plewig G, Cunliffe W, Binder N, Hoesschen K. Efficacy of an oral con-
traceptive containing EE 0.03 mg and CMA 2 mg (Belara) in moderate 
acne resolution: A randomized, double-blind, placebo-controlled Phase 
III trial. Contraception. 2009;80(1):25–33.
 19. Kerscher M, Reuther T, Bayrhammer J, Schramm G. Effects of an oral 
contraceptive containing chlormadinone and ethinylestradiol on acne-
prone skin of women of different age groups: An open-label, single-
centre, Phase IV study. Clin Drug Investig. 2008;28(11):703–711.
 20. Schramm G, Heckes B. Switching hormonal contraceptives to a 
 chlormadinone acetate-containing oral contraceptive. The contraceptive 
switch study. Contraception. 2007;76(2):84–90.
 21. Sabatini R, Orsini G, Cagiano R, Loverro G. Noncontraceptive benefits 
of two combined oral contraceptives with antiandrogenic properties 
among adolescents. Contraception. 2007;76(2):342–347.
 22. Winkler UH, Daume E, Sudik R, et al. A comparative study of the 
 hemostatic effects of two monophasic oral contraceptives containing 
30 mcg ethinylestradiol and either 2 mg chlormadinone acetate or 
150 mcg desogestrel. Eur J Contracept Reprod Health Care. 1999;4: 
145–154.
 23. Winkler UH, Röhm P, Höschen K. An open-label, comparative study 
of the effects of a dose-reduced oral contraceptive containing 0.02 mg 
ethinylestradiol/2 mg chlormadinone acetate on hemostatic parameters 
and lipid and carbohydrate metabolism variables. Contraception. 2010; 
81(5):391–400.
 24. Winkler UH, Sudik R. The effects of two monophasic oral contraceptives 
containing 30 mcg of ethinylestradiol and either 2 mg of chlormadinone 
acetate or 0.15 mg of desogestrel on lipid, hormone and metabolic 
parameters. Contraception. 2009;79(1):15–23.
 25. Cagnacci A, Ferrari S, Tirelli A, Zanin R, Volpe A. Insulin sensitivity 
and lipid metabolism with oral contraceptives containing chlormadi-
none acetate or desogestrel: A randomized trial. Contraception. 2009; 
79(2):111–116.
 26. Zahradnik HP, Hanjalic-Beck A. Efficacy, safety and sustainability of 
treatment continuation and results of an oral contraceptive containing 
30 mcg ethinyl estradiol and 2 mg chlormadinone acetate, in long-term 
usage (up to 45 cycles) – an open-label, prospective, noncontrolled, 
office-based Phase III study. Contraception. 2008;77(5):337–343.
 27. Schramm G, Steffens D. Contraceptive efficacy and tolerability of 
chlormadinone acetate 2 mg ethiniylestradiol 0.03 mg (Belara). Clin 
Drug Investig. 2002;22(4):221–231.
 28. Uras R, Orrù M, Etzi R, et al. Evidence that in healthy young women, 
a six-cycle treatment with oral contraceptive containing 30 mcg of 
ethinylestradiol plus 2 mg of chlormadinone acetate reduces fat mass. 
Contraception. 2009;79(2):117–121.
 29. Fruzzetti F, Lello S, Lazzarini V, et al. The oral contraceptive  containing 
30 microg of ethinylestradiol plus 3 mg of drospirenone is able to 
antagonize the increase of extracellular fluid occurring in healthy young 
women during the luteal phase of the menstrual cycle: An observational 
study. Contraception. 2007;75(3):199–203.
 30. Lello S, Vittori G, Paoletti AM, Sorge R, Guardianelli F, Melis GB. 
Effects on body weight and body composition of a low-dose estro-
progestin containing ethinylestradiol 20 microg plus levonorgestrel 
100 microg. Gynecol Endocrinol. 2007;23(11):632–637.
